IGHE and lung carcinoma: Since long-term clinical follow-up data was lacking for patients with stage I and II lung cancer and there was significant variability in the treatment of patients with stage III NSCLC, we could not analyze the association between serum total IgE level and clinical prognosis for these groups of patients.